@rago_carlo 3h3 hours ago More Replying to @biggercapital Self-assured, soaked in bleach, he's part of the problem and simultaneously irrelevant. I guess he missed the lesson on Type II errors. Patients deserve an unbiased consideration of the data.
0 replies 4 retweets 7 likes Reply Retweet 4 Like 7 Direct message
Carlo Rago ?
@rago_carlo 4h4 hours ago More Replying to @blackened123 Any day, but maybe as much as 3 months. 0-3 months is my guess.
2 replies 3 retweets 8 likes Reply 2 Retweet 3 Like 8 Direct message
Carlo Rago ?
@rago_carlo 4h4 hours ago More Replying to @RobertAnema I think they reported the number. Likely 33 untreated as you suggest here.
0 replies 0 retweets 0 likes Reply Retweet Like Direct message
Carlo Rago ?
@rago_carlo 4h4 hours ago More Ex#2: On refresh, the mOS delta between MGMT-M vs MGMT-U expanded (albeit modestly), as predicted. Due to inactivation of this key DNA repair enzyme, M have 400% more mutations than U tumors (true prior to temozolomide) + DCVax is designed to target mutant epitopes. $NWBO + $BMY?
0 replies 3 retweets 14 likes Reply Retweet 3 Like 14 Direct message Show this thread
Carlo Rago ?
@rago_carlo 4h4 hours ago More Ex#1: Survival data improved on refresh, as I predicted. Specifically, the 3yr survival improved > 2 yr > mOS as one would predict from onboarding of censored patients in an (effective) immunotherapy setting, i.e. magnification of the long tail. $NWBO #DCVax, $BMY $GSK $MRK $NVS?
0 replies 2 retweets 11 likes Reply Retweet 2 Like 11 Direct message Show this thread
Carlo Rago ?
@rago_carlo 4h4 hours ago More Replying to @blackened123 There is a strong chorus of stakeholders that are now more than satisfied with the length of follow-up and thankfully the company has suggested that they are in the process of wrapping up, see Linda Powers' quote here: https://nwbio.com/updated-interim-data-from-phase-3-trial-of-dcvax-l-for-glioblastoma/ …
1 reply 0 retweets 1 like Reply 1 Retweet Like 1 Direct message
Carlo Rago ?
@rago_carlo 4h4 hours ago More Replying to @FloatServe1 Thank you, FloatServe. It was a nice trip. I was surprised by the update, which strengthened my conviction. I'll share a couple updates in this tread.
0 replies 2 retweets 4 likes Reply Retweet 2 Like 4 Direct message
Carlo Rago ?
@rago_carlo 5h5 hours ago More Replying to @Stephan03058682 Thank you, Superinvestor1. Company appears to be moving to lock and analyze to topline. Very much looking forward to combo trials ASAP.
0 replies 0 retweets 0 likes Reply Retweet Like Direct message
Carlo Rago ?
@rago_carlo 5h5 hours ago More Replying to @MongielloKevin Thank you, Kevin. I'm looking forward to $NWBO realizing full value. Can't wait for the combos. Winter is coming, shorts need to go back in the closet.
0 replies 2 retweets 9 likes Reply Retweet 2 Like 9 Direct message
Carlo Rago ?
@rago_carlo 5h5 hours ago More Replying to @necdicky @TiltMyBrain Thanks for reading, Dicky. Looking forward to $NWBO realizing full value.
0 replies 0 retweets 4 likes Reply Retweet Like 4 Direct message
Carlo Rago ?
@rago_carlo 5h5 hours ago More Replying to @Spreadburn It been fun. If you have followed over the past 24 months, you will note that there have been no material criticisms, save "unblind."
0 replies 2 retweets 4 likes Reply Retweet 2 Like 4 Direct message
0 replies 0 retweets 0 likes Reply Retweet Like Direct message
Carlo Rago ?
@rago_carlo 5h5 hours ago More Replying to @justinkeister5 As you probably know, Linda Powers has suggested they are in the process of rolling things up for lock and analysis. We are fortunate to be deep into the follow-ups, which will allow a great comparison to Optune, any farther would be diminishing returns. https://nwbio.com/updated-interim-data-from-phase-3-trial-of-dcvax-l-for-glioblastoma/ …
0 replies 2 retweets 8 likes Reply Retweet 2 Like 8 Direct message
Carlo Rago ?
@rago_carlo 5h5 hours ago More Replying to @BabcockB38 Done. Thanks for following NWBO.
0 replies 0 retweets 3 likes Reply Retweet Like 3 Direct message
Market Data 
Markets 
AI
